pelvic organ prolapse (POP)
Conditions
Interventions
Estrogen group:Patients will be treated with promestriene cream 0.5g twice a week transvaginally for 6 weeks prior to surgery
Control group:Patients will undergo surgery 6 weeks after participating without pharmacological preparation
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
Female
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Female, 50 to 75 years of age (including 50 and 75 years of age); 2. Diagnosed with uterine prolapse stage III or IV combined with anterior vaginal wall prolapse stage III or IV, according to the Pelvic Organ Prolapse Quantification [POP-Q] system; 3. Have an indication for transvaginal reconstructive pelvic surgery with mesh.
Exclusion criteria
Exclusion criteria: Patients who has any one of the following can not be enrolled into this study: 1. Patients who had received oral or transdermal estrogen therapy within 1 years before participating in the study; 2. Women being pregnant or lactating; 3. Patients with a history of anti-incontinence or prolapse surgery; 4. Patients with current urinary stress incontinence; 5. Patients with any contraindication for local estrogen application or any type of cancer; 6. Patients not able to tolerate the laparoscopic procedures; 7. Patients with a need for concomitant surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of mesh exposure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients achieving anatomic success;Proportion of patients achieving subjective satisfaction;Vaginal swab culture result post-operation; | — |
Countries
China
Contacts
Public ContactLan Zhu
Outcome results
None listed